NBC News 5/14/24: Wegovy users keep weight off for 4 years, new analysis finds

“The 17,604-patient trial tested Wegovy not for weight loss but for its heart protective benefits for overweight and obese patients who had preexisting heart disease but not diabetes. Participants were not required to track diet and exercise because it was not an obesity study…”

“Patients in the trial, called Select, lost an average of nearly 10% of their total body weight after 65 weeks on Wegovy. That percentage weight-loss was roughly sustained year-on-year until the end of about four years, where weight loss stood at 10.2%…”

“A third new analysis on Select published by Novo on Tuesday showed that the heart protective benefits of Wegovy to patients in the trial occurred regardless of their weight before starting on the drug and regardless of how much weight they lose on it.”

“The weight loss in the heart trial was less than the average of 15% weight loss in earlier Wegovy obesity studies”

Related blog posts:

• Weight Gain If Semaglutide Stopped
• AGA Guidance: GLP-1 Receptor Agonists Prior to Endoscopy
• How Many Kids Would Be Good Candidates for Bariatric Surgery?
• What Really Causes Obesity and Weight Bias
• Semaglutide in Adolescent Obesity
• AGA Guidelines for Adults with Obesity
• Does Motivational Interviewing Help Long-Term Outcomes for Obesity?
• Time to Change the Medical Treatment and Attitudes Directed at Obesity?
• How to Talk About Childhood Obesity